Ayşe Nur DEMİRAL
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayşe Nur DEMİRAL has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Doğukan AKÇAY
DOKUZ EYLÜL UNİVERSITY, FACULTY OF MEDICINE, DEPARTMENT OF RADIATION ONCOLOGY
2 shared publications - Kadir Akgüngör
Department of Atomic and Molecular Physics, Dokuz Eylul University, Izmir, Turkey
2 shared publications - Mehmet Çağrı Duymaz
Department of Radiation Oncology, Dokuz Eylul University, 35320 Izmir, Türkiye
2 shared publications - Nur Olgun
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Oncology, İzmir, Turkey
2 shared publications Alptekin Arifoglu
Radiation Oncology Department Acıbadem Altunizade Hospital Istanbul Turkey
1 shared publicationAyten Kayı Cangır
1 shared publication
Latest Publications
- Open Access
- 1 September 2026
- Published by Wiley in International Journal of Cancer
Pretreatment EBV ‐ DNA / TLG ‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study
Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations. We retrospectively analyzed 86 eligible nonmetastatic NPC patients treated with definitive radiotherapy (2010–2024) at a single nonendemic‐region institution. EBV‐DNA (prespecified cutoff 3500 copies/mL) and TLG (cutoff 200, ROC‐derived within this cohort) were dichotomized. Both were available in 59/86 patients (68.6%), who differed from the rest in nodal and overall stage and in RT technique. Baseline PET/CT was in‐house in 57 of 86 patients, and a robustness analysis in that subgroup is reported. Given limited events (13 PFS, 9 OS), Cox analyses are exploratory and were supplemented with penalized regression and bootstrap validation. At a median follow‐up of 75.5 months, 5‐year PFS and OS for the whole cohort ( n = 86) were 81.1% and 85.9%. The EBV‐DNA high /TLG high subgroup remained associated with inferior PFS after adjustment in an exploratory model (adjusted HR = 3.97, 95% CI: 1.32–11.93) and, in a single‐variable model, with inferior OS (HR = 4.13, 95% CI: 1.10–15.52). Discrimination was comparable to the individual‐biomarker model for PFS and lower for OS. Five‐year PFS fell monotonically across the four risk groups in the complete‐case cohort ( n = 59; 89.7%–58.3%). OS differed across groups (log‐rank p = 0.044) but was not strictly monotonic, with wide, overlapping confidence intervals. This two‐biomarker model is hypothesis‐generating and needs prospective, multicenter validation before any consideration of risk‐adapted treatment.
- 1 September 2026
- Published by Wiley in International Journal of Cancer
Open AccessPretreatment EBV ‐ DNA / TLG ‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study
Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations. We retrospectively analyzed 86 eligible nonmetastatic NPC patients treated with definitive radiotherapy (2010–2024) at a single nonendemic‐region institution. EBV‐DNA (prespecified cutoff 3500 copies/mL) and TLG (cutoff 200, ROC‐derived within this cohort) were dichotomized. Both were available in 59/86 patients (68.6%), who differed from the rest in nodal and overall stage and in RT technique. Baseline PET/CT was in‐house in 57 of 86 patients, and a robustness analysis in that subgroup is reported. Given limited events (13 PFS, 9 OS), Cox analyses are exploratory and were supplemented with penalized regression and bootstrap validation. At a median follow‐up of 75.5 months, 5‐year PFS and OS for the whole cohort ( n = 86) were 81.1% and 85.9%. The EBV‐DNA high /TLG high subgroup remained associated with inferior PFS after adjustment in an exploratory model (adjusted HR = 3.97, 95% CI: 1.32–11.93) and, in a single‐variable model, with inferior OS (HR = 4.13, 95% CI: 1.10–15.52). Discrimination was comparable to the individual‐biomarker model for PFS and lower for OS. Five‐year PFS fell monotonically across the four risk groups in the complete‐case cohort ( n = 59; 89.7%–58.3%). OS differed across groups (log‐rank p = 0.044) but was not strictly monotonic, with wide, overlapping confidence intervals. This two‐biomarker model is hypothesis‐generating and needs prospective, multicenter validation before any consideration of risk‐adapted treatment.
- 1 January 2025
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 40 (3) , 218-224
The Comparison of Volumetric Optimization and Reference Line Optimization on Organs at Risk Doses in Three-dimensional Vaginal Vault Brachytherapy
- 1 January 2025
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 40 (3) , 218-224
The Comparison of Volumetric Optimization and Reference Line Optimization on Organs at Risk Doses in Three-dimensional Vaginal Vault Brachytherapy
- 15 July 2023
- Published by Springer Nature in Child's Nervous System
- Vol. 40 (1) , 123-133
Pediatric paravertebral tumors: analysis of 96 patients
Purpose The most important complication of paravertebral tumors is cord compression (CC), which is an oncologic emergency. Early and appropriate intervention is important in terms of reducing morbidity and mortality. Here, we report our clinical experience with paravertebral tumors. Methods The files of patients who were followed up for benign/malignant paravertebral tumors between 1988 and 2022 were evaluated retrospectively. Results There were 96 patients with paravertebral tumors. The median age at diagnosis was 5 years (1 month–17 years). The male/female ratio was 1.13. The median time to diagnosis was 4 weeks (0–28 weeks). The most common presenting complaint was pain (62.5%). The diagnosis distribution was as follows: sympathetic nervous system (SNS) tumors (n: 38), soft tissue sarcomas (STS) (n: 23), Langerhans cell histiocytosis (LCH) (n: 12), central nervous system (CNS) tumors (n: 9), germ cell tumor (n: 6), lymphomas (n: 4), and benign tumors (n: 4). Sixty-five patients (67.7%) had CC, 40% of whom received chemotherapy as first-line treatment. Decompression surgery was performed in 58.5% of the patients. For patients with CC, 26 patients had advanced disease at admission. Serious neurologic sequelae were observed in seventeen (17.7%) patients. Conclusion Pain and neurological findings in childhood are warning signs for paravertebral tumors and CC. A detailed neurologic examination and radiodiagnostic imaging should be performed, and a definitive diagnosis should be made quickly. Anticancer treatment should be planned multidisciplinary. Decompression surgery should be discussed for patients with severe neurological deficits. Childhood cancers are chemosensitive; if possible, treatment should be initiated with chemotherapy to avoid neurological sequelae.
- 15 July 2023
- Published by Springer Nature in Child's Nervous System
- Vol. 40 (1) , 123-133
Pediatric paravertebral tumors: analysis of 96 patients
Purpose The most important complication of paravertebral tumors is cord compression (CC), which is an oncologic emergency. Early and appropriate intervention is important in terms of reducing morbidity and mortality. Here, we report our clinical experience with paravertebral tumors. Methods The files of patients who were followed up for benign/malignant paravertebral tumors between 1988 and 2022 were evaluated retrospectively. Results There were 96 patients with paravertebral tumors. The median age at diagnosis was 5 years (1 month–17 years). The male/female ratio was 1.13. The median time to diagnosis was 4 weeks (0–28 weeks). The most common presenting complaint was pain (62.5%). The diagnosis distribution was as follows: sympathetic nervous system (SNS) tumors (n: 38), soft tissue sarcomas (STS) (n: 23), Langerhans cell histiocytosis (LCH) (n: 12), central nervous system (CNS) tumors (n: 9), germ cell tumor (n: 6), lymphomas (n: 4), and benign tumors (n: 4). Sixty-five patients (67.7%) had CC, 40% of whom received chemotherapy as first-line treatment. Decompression surgery was performed in 58.5% of the patients. For patients with CC, 26 patients had advanced disease at admission. Serious neurologic sequelae were observed in seventeen (17.7%) patients. Conclusion Pain and neurological findings in childhood are warning signs for paravertebral tumors and CC. A detailed neurologic examination and radiodiagnostic imaging should be performed, and a definitive diagnosis should be made quickly. Anticancer treatment should be planned multidisciplinary. Decompression surgery should be discussed for patients with severe neurological deficits. Childhood cancers are chemosensitive; if possible, treatment should be initiated with chemotherapy to avoid neurological sequelae.
- 10 April 2023
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 7 (3) , 50-57
Comparison of Hybrid Techniques with 3D-Conformal Radiotherapy in Patients with Lung Cancer
Purpose: It’s postulated that hybrid techniques (HT) with lower weighting of IMRT/VMAT component would improve lung dose-volume parameters despite some disadvantage in PTV homogeneity index (HI) and target coverage (TC). Material and Methods: Conformal plans were prepared using 6-10-15 MV-X photon energies while IMRT/VMAT plans of HTs were prepared using 6MV-X. Four HTs were developed having two different ratios (10% and 50%) of IMRT/VMAT component (h-IMRT1, h-IMRT2 and h-VMAT1, h-VMAT2, respectively). HTs were compared with 3D-CRT in terms of HI and TC for PTV, and total lung (TL) and contralateral lung (CL) V5Gy, V10Gy, V20Gy and mean lung dose (MLD). Results: All HTs were advantageous for HI and TC, while disadvantageous for TL and CL-V5Gy. H-IMRT2 provided better TC than h-IMRT1, and so did h-VMAT2 compared to h-VMAT1. Lower weighting of IMRT/VMAT decreased TL and CL-V5Gy in HTs. In addition, h-IMRT1 decreased TL and CL-MLD and CL-V20Gy compared to h-IMRT2, while h-VMAT2 decreased TL-V20Gy and CL-MLD compared to h-VMAT2. Conclusion: In the RT of lung tumors close to vertebra, it may be appropriate to suggest a ratio of IMRT/VMAT component about 10% in order to decrease the low and intermediate dose-wash lung volume, if HI and TC values are acceptable.
- 10 April 2023
- Published by Dokuz Eyul Universitesi Saglik Bilimleri Enstitusu in Journal of Basic and Clinical Health Sciences
- Vol. 7 (3) , 50-57
Comparison of Hybrid Techniques with 3D-Conformal Radiotherapy in Patients with Lung Cancer
Purpose: It’s postulated that hybrid techniques (HT) with lower weighting of IMRT/VMAT component would improve lung dose-volume parameters despite some disadvantage in PTV homogeneity index (HI) and target coverage (TC). Material and Methods: Conformal plans were prepared using 6-10-15 MV-X photon energies while IMRT/VMAT plans of HTs were prepared using 6MV-X. Four HTs were developed having two different ratios (10% and 50%) of IMRT/VMAT component (h-IMRT1, h-IMRT2 and h-VMAT1, h-VMAT2, respectively). HTs were compared with 3D-CRT in terms of HI and TC for PTV, and total lung (TL) and contralateral lung (CL) V5Gy, V10Gy, V20Gy and mean lung dose (MLD). Results: All HTs were advantageous for HI and TC, while disadvantageous for TL and CL-V5Gy. H-IMRT2 provided better TC than h-IMRT1, and so did h-VMAT2 compared to h-VMAT1. Lower weighting of IMRT/VMAT decreased TL and CL-V5Gy in HTs. In addition, h-IMRT1 decreased TL and CL-MLD and CL-V20Gy compared to h-IMRT2, while h-VMAT2 decreased TL-V20Gy and CL-MLD compared to h-VMAT2. Conclusion: In the RT of lung tumors close to vertebra, it may be appropriate to suggest a ratio of IMRT/VMAT component about 10% in order to decrease the low and intermediate dose-wash lung volume, if HI and TC values are acceptable.
- 3 April 2023
- Published by Dokuz Eylul Universitesi Tip Fakultesi Dergisi in Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi
- Vol. 37 (1) , 67-77
EVALUATION OF CLINICAL STUDIES USING KNOWLEDGE BASED PLANNING METHODS IN THE RADIOTHERAPY OF PROSTATE CANCER WITH VOLUMETRIC MODULATED ARC THERAPY
Bilgi Tabanlı Planlama (“Knowledge Based Planningˮ-KBP), klinik olarak kabul edilebilir Yoğunluk Ayarlı Radyoterapi (“Intensity Modulated Radiotherapy”-IMRT) ve Hacimsel Modülasyonlu Ark Tedavisi (“Volumetric Modulated Arc Therapy”-VMAT) planlarını minimum iş akışıyla optimize etmek için bilgi tabanlı modeller (“Knowledge Based Model”–KBM) kullanarak plan kalitesini standart hale getirmeyi amaçlar. KBP, Risk Altındaki Organlar (‟Organ at Risk”-OAR) için ulaşılabilir Doz-Volüm Histogramı (DVH)’nı tahmin eder ve her bir yeni hasta için ideal optimizasyon hedefleri sağlar. KBP modeli, plan kalitesini iyileştirir, plan tutarlılığını koruyarak planlayıcılar arası değişkenliği azaltır ve simülasyondan tedavi başlangıcına dek geçen süreyi kısaltır. Bu derlemede prostat kanserinin VMAT tekniği ile tedavisinde KBP tabanlı yöntemlerin kullanıldığı klinik çalışmaların sonuçları incelendi. “Knowledge-based treatment planning”, “prostate cancer”, “VMAT” anahtar kelimeleri kullanılarak “PubMed” tarama motorunda “Clinical Trial” kategorisindeki İngilizce olarak yayınlanmış makalelerin taranması sonucu ulaşılan beş adet çalışma derleme kapsamına alındı. Bu klinik çalışmaların tümünde temelde KBP modelinin dozimetrik ve mekanik performansını değerlendirmek ve optimize etmek istenmiştir. Bu nedenle her bir kliniğin deneyimine göre hazırlanan manuel planlar, KBP ile oluşturulan otomatik planlar ile karşılaştırılmıştır. Prostat kanserinin VMAT planlamasında KBP kullanımı, doğrulama çalışmalarında, güçlü bir şekilde performans göstermiştir. KBP yöntemleri, plan kalitesi açısından genellikle uzman seviyesindeki planlayıcılara eşdeğerdir ancak ön sonuçlar, önemli ölçüde daha gelişmiş olduklarını göstermektedir. Hedef volüm ile örtüşen OAR volümlerinin dikkate alındığı KBP modellerinin örtüşme volüm histogramı (“overlap volüme histogram”-OVH) rehberliğinde daha hassas ve doğru doz tahminleri yapabileceği düşünülmektedir. KBP yöntemlerinin uygulaması sırasında dozimetrik ve mekanik performansın yanı sıra hastaya özgü kalite güvenirliğini (“Quality Assurance” –QA) doğrulamak da çok önemlidir.
- 3 April 2023
- Published by Dokuz Eylul Universitesi Tip Fakultesi Dergisi in Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi
- Vol. 37 (1) , 67-77
EVALUATION OF CLINICAL STUDIES USING KNOWLEDGE BASED PLANNING METHODS IN THE RADIOTHERAPY OF PROSTATE CANCER WITH VOLUMETRIC MODULATED ARC THERAPY
Bilgi Tabanlı Planlama (“Knowledge Based Planningˮ-KBP), klinik olarak kabul edilebilir Yoğunluk Ayarlı Radyoterapi (“Intensity Modulated Radiotherapy”-IMRT) ve Hacimsel Modülasyonlu Ark Tedavisi (“Volumetric Modulated Arc Therapy”-VMAT) planlarını minimum iş akışıyla optimize etmek için bilgi tabanlı modeller (“Knowledge Based Model”–KBM) kullanarak plan kalitesini standart hale getirmeyi amaçlar. KBP, Risk Altındaki Organlar (‟Organ at Risk”-OAR) için ulaşılabilir Doz-Volüm Histogramı (DVH)’nı tahmin eder ve her bir yeni hasta için ideal optimizasyon hedefleri sağlar. KBP modeli, plan kalitesini iyileştirir, plan tutarlılığını koruyarak planlayıcılar arası değişkenliği azaltır ve simülasyondan tedavi başlangıcına dek geçen süreyi kısaltır. Bu derlemede prostat kanserinin VMAT tekniği ile tedavisinde KBP tabanlı yöntemlerin kullanıldığı klinik çalışmaların sonuçları incelendi. “Knowledge-based treatment planning”, “prostate cancer”, “VMAT” anahtar kelimeleri kullanılarak “PubMed” tarama motorunda “Clinical Trial” kategorisindeki İngilizce olarak yayınlanmış makalelerin taranması sonucu ulaşılan beş adet çalışma derleme kapsamına alındı. Bu klinik çalışmaların tümünde temelde KBP modelinin dozimetrik ve mekanik performansını değerlendirmek ve optimize etmek istenmiştir. Bu nedenle her bir kliniğin deneyimine göre hazırlanan manuel planlar, KBP ile oluşturulan otomatik planlar ile karşılaştırılmıştır. Prostat kanserinin VMAT planlamasında KBP kullanımı, doğrulama çalışmalarında, güçlü bir şekilde performans göstermiştir. KBP yöntemleri, plan kalitesi açısından genellikle uzman seviyesindeki planlayıcılara eşdeğerdir ancak ön sonuçlar, önemli ölçüde daha gelişmiş olduklarını göstermektedir. Hedef volüm ile örtüşen OAR volümlerinin dikkate alındığı KBP modellerinin örtüşme volüm histogramı (“overlap volüme histogram”-OVH) rehberliğinde daha hassas ve doğru doz tahminleri yapabileceği düşünülmektedir. KBP yöntemlerinin uygulaması sırasında dozimetrik ve mekanik performansın yanı sıra hastaya özgü kalite güvenirliğini (“Quality Assurance” –QA) doğrulamak da çok önemlidir.
- 4 August 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (11) , 1050-1059
Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study
Objective We identified factors influencing outcomes in patients with medically inoperable early‐stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Methods We retrospectively analyzed 431 patients with stage I‐II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction, and biologically effective dose with an α/β ratio of 10 (BED10); tumor location; and treatment center were evaluated for associations with overall survival (OS), local control (LC), and toxicity. Results Median follow‐up time was 27 months (range 1–115); median SABR dose was 54Gy (range 30–70) given in a median 3 fractions (range 1–10); median BED10 was151 Gy (range 48–180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%), and 100Gy (p =0.011), adenocarcinoma (p =0.025), and complete response on first evaluation (p =0.007) predicted favorable LC. BED10>120Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1–3.2,p =0.019) and tumor size (p =0.003) predicted favorable OS. No grade 4‐5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]), and rib fracture (1 [0.2%]). Conclusion SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10>120 Gy was needed for better LC and OS for large, non‐adenocarcinoma tumors.
- 4 August 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (11) , 1050-1059
Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study
Objective We identified factors influencing outcomes in patients with medically inoperable early‐stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Methods We retrospectively analyzed 431 patients with stage I‐II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction, and biologically effective dose with an α/β ratio of 10 (BED10); tumor location; and treatment center were evaluated for associations with overall survival (OS), local control (LC), and toxicity. Results Median follow‐up time was 27 months (range 1–115); median SABR dose was 54Gy (range 30–70) given in a median 3 fractions (range 1–10); median BED10 was151 Gy (range 48–180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%), and 100Gy (p =0.011), adenocarcinoma (p =0.025), and complete response on first evaluation (p =0.007) predicted favorable LC. BED10>120Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1–3.2,p =0.019) and tumor size (p =0.003) predicted favorable OS. No grade 4‐5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]), and rib fracture (1 [0.2%]). Conclusion SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10>120 Gy was needed for better LC and OS for large, non‐adenocarcinoma tumors.